Total Payments
$394,557
2024 Payments
$29,806
Companies
22
Transactions
232
Medicare Patients
771
Medicare Billing
$247,867
Payment Breakdown by Category
Consulting$220,830 (56.0%)
Research$153,174 (38.8%)
Travel$13,484 (3.4%)
Food & Beverage$4,969 (1.3%)
Other$2,000 (0.5%)
Education$99.99 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $220,830 | 63 | 56.0% |
| Unspecified | $153,174 | 16 | 38.8% |
| Travel and Lodging | $13,484 | 64 | 3.4% |
| Food and Beverage | $4,969 | 87 | 1.3% |
| Honoraria | $2,000 | 1 | 0.5% |
| Education | $99.99 | 1 | 0.0% |
Payments by Type
General
$241,384
216 transactions
Research
$153,174
16 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AbbVie Inc. | $152,701 | 14 | $0 (2021) |
| Incyte Corporation | $96,127 | 136 | $0 (2024) |
| Daiichi Sankyo Inc. | $93,550 | 26 | $0 (2024) |
| VectivBio AG | $8,250 | 1 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $8,000 | 4 | $0 (2024) |
| ModernaTX, Inc. | $8,000 | 2 | $0 (2022) |
| Millennium Pharmaceuticals, Inc. | $7,163 | 4 | $0 (2017) |
| Pharmacosmos Therapeutics Inc. | $6,200 | 5 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $3,494 | 10 | $0 (2019) |
| Celgene Corporation | $2,871 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $29,806 | 25 | Incyte Corporation ($8,892) |
| 2023 | $18,705 | 28 | Incyte Corporation ($10,787) |
| 2022 | $25,166 | 30 | Incyte Corporation ($15,674) |
| 2021 | $89,996 | 28 | Daiichi Sankyo Inc. ($77,500) |
| 2020 | $111,398 | 24 | AbbVie Inc. ($91,500) |
| 2019 | $88,961 | 53 | AbbVie, Inc. ($61,116) |
| 2018 | $14,897 | 22 | Incyte Corporation ($12,040) |
| 2017 | $15,628 | 22 | Incyte Corporation ($7,840) |
All Payment Transactions
232 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| Category: Rare Disease | ||||||
| 12/07/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $191.92 | General |
| Category: ONCOLOGY | ||||||
| 09/16/2024 | ZOLL Medical Corporation | Defibrillator (Device) | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| Category: Resuscitation | ||||||
| 09/04/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| Category: Rare Disease | ||||||
| 08/08/2024 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $7,535.00 | General |
| 08/08/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $326.84 | General |
| 08/08/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $236.19 | General |
| 08/08/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $96.62 | General |
| 08/08/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $59.48 | General |
| 08/08/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $53.24 | General |
| 08/08/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $31.11 | General |
| 08/08/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $29.87 | General |
| 08/07/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $219.00 | General |
| 08/07/2024 | National Marrow Donor Program | — | Food and Beverage | In-kind items and services | $214.56 | General |
| 08/07/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $139.42 | General |
| 08/07/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $31.74 | General |
| 08/07/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $24.05 | General |
| 06/17/2024 | VectivBio AG | — | Consulting Fee | Cash or cash equivalent | $8,250.00 | General |
| 05/31/2024 | CSL Behring | — | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| 05/20/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: Rare Disease | ||||||
| 05/02/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| Category: Rare Disease | ||||||
| 04/28/2024 | National Marrow Donor Program | — | Food and Beverage | In-kind items and services | $214.51 | General |
| 04/05/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $42.12 | General |
| 02/22/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $109.89 | General |
| Category: Hematology/Oncology | ||||||
| 01/30/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Consulting Fee | In-kind items and services | $1,600.00 | General |
| Category: HEMATOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| M16-043 | AbbVie Inc. | $91,500 | 7 |
| M16-043 | AbbVie, Inc. | $61,116 | 6 |
| NN9388-4606 | Novo Nordisk AS | $400.00 | 1 |
| A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) | Millennium Pharmaceuticals, Inc. | $97.20 | 1 |
| A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation | Astellas Pharma Global Development | $60.01 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 197 | 719 | $381,215 | $78,928 |
| 2022 | 4 | 196 | 579 | $304,308 | $61,833 |
| 2021 | 4 | 193 | 596 | $278,668 | $62,908 |
| 2020 | 4 | 185 | 488 | $216,916 | $44,197 |
Total Patients
771
Total Services
2,382
Medicare Billing
$247,867
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 109 | 346 | $211,427 | $40,549 | 19.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 50 | 331 | $141,746 | $33,145 | 23.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 24 | 26 | $20,930 | $3,671 | 17.5% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 14 | 16 | $7,112 | $1,564 | 22.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 118 | 327 | $197,562 | $39,380 | 19.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 34 | 193 | $78,596 | $16,914 | 21.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 32 | 47 | $18,682 | $3,507 | 18.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 12 | 12 | $9,468 | $2,032 | 21.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 103 | 290 | $148,037 | $35,271 | 23.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 35 | 238 | $100,520 | $21,030 | 20.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 41 | 53 | $17,880 | $4,439 | 24.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 14 | 15 | $12,231 | $2,168 | 17.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 100 | 269 | $125,231 | $24,562 | 19.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 25 | 142 | $58,930 | $12,875 | 21.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 44 | 60 | $19,019 | $3,966 | 20.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 16 | 17 | $13,736 | $2,794 | 20.3% |
About Dr. Yi-Bin Chen, MD
Dr. Yi-Bin Chen, MD is a Internal Medicine healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/04/2005. The National Provider Identifier (NPI) number assigned to this provider is 1356332639.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Yi-Bin Chen, MD has received a total of $394,557 in payments from pharmaceutical and medical device companies, with $29,806 received in 2024. These payments were reported across 232 transactions from 22 companies. The most common payment nature is "Consulting Fee" ($220,830).
As a Medicare-enrolled provider, Chen has provided services to 771 Medicare beneficiaries, totaling 2,382 services with total Medicare billing of $247,867. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Boston, MA
- Active Since 11/04/2005
- Last Updated 09/07/2012
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1356332639
Products in Payments
- VENCLEXTA (Drug) $91,584
- Venclexta (Drug) $61,116
- JAKAFI (Drug) $40,826
- ULTOMIRIS (Biological) $8,000
- ENTYVIO (Biological) $7,163
- MONOFERRIC (Drug) $6,200
- Enhertu (Drug) $3,942
- Imbruvica (Drug) $3,494
- Revlimid (Drug) $2,817
- Rezlidhia (Drug) $2,152
- Defibrillator (Device) $450.00
- LIVTENCITY (Drug) $111.54
- XOSPATA (Drug) $60.01
- Idhifa (Drug) $11.91
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Boston
Michael Mendelsohn, M.d, M.D
Internal Medicine — Payments: $4.6M
Internal Medicine $4.6M
David Schenkein, Md, MD
Internal Medicine — Payments: $4.0M
Internal Medicine $4.0M
Dr. John Fallon, M.d, M.D
Internal Medicine — Payments: $2.5M
Internal Medicine $2.5M
Dr. David Scadden, Md, MD
Internal Medicine — Payments: $2.2M
Internal Medicine $2.2M
Dr. James Januzzi, Md, MD
Internal Medicine — Payments: $1.8M
Internal Medicine $1.8M
Dr. Marilyn Pike, Md Phd, MD PHD
Internal Medicine — Payments: $1.5M
Internal Medicine $1.5M